<DOC>
	<DOC>NCT00457392</DOC>
	<brief_summary>This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.</brief_summary>
	<brief_title>A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients with locally advanced/metastatic nonsmall cell lung cancer Prior treatment with no more than 2 chemotherapy regimens including a platinumbased regimen Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the exception of bevacizumab) or other angiogenesis inhibitors History of or known brain metastases</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>sunitinib</keyword>
	<keyword>erlotinib</keyword>
	<keyword>Phase 3</keyword>
</DOC>